RHB-102 is a proprietary, oral, extended-release (24 hours), once-daily pill formulation of the 5-HT3 receptor antagonist antiemetic drug ondansetron.
RHB-102 is being developed for several gastrointestinal indications:
* Bekinda® is the proposed tradename for RHB-102, which is subject to review by the FDA at the time of NDA filing